Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.
Cizzle Biotechnology Holdings PLC has secured an additional £250,000 through convertible loan notes from investor Frazer Lang to support the commercialization of its CIZ1B biomarker test for early lung cancer detection. This funding will aid in expanding the test’s availability in North America, the UK, and Europe, and supports ongoing collaborations with medical partners, including the NHS, to enhance early cancer diagnosis capabilities.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics company specializing in the development of early cancer detection tests. Its primary product, the CIZ1B biomarker test, is a non-invasive blood test designed to detect early-stage lung cancer. The company has established commercial and collaborative partnerships to advance its proprietary technology and is listed on the London Stock Exchange.
Average Trading Volume: 1,463,715
Technical Sentiment Signal: Hold
Current Market Cap: £6.74M
Learn more about CIZ stock on TipRanks’ Stock Analysis page.